National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Aspirin and Cancer Prevention
    Posted: 12/07/2005



Links to NCI Materials






Closed Clinical Trials



Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Related Pages
Search for Clinical Trials
NCI's PDQ® registry of cancer clinical trials.

Cyclooxygenase (COX) Inhibitors
A collection of material about cyclooxygenase (COX) inhibitors - drugs that are being tested for a variety of therapeutic purposes, including the prevention and treatment of certain cancers.

Cancer Prevention
Cancer prevention information from the National Cancer Institute, including prevention information for specific cancers.
Links to NCI Materials

Numerous studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin may hold promise in helping to prevent cancer. NSAIDs block cyclooxygenase (COX) enzymes, which are produced by the body when there is inflammation and are also produced by precancerous tissues.

This page includes links to information about aspirin and cancer. For information about other NSAIDs under study, see Cyclooxygenase (COX) Inhibitors.

General Information
Nonsteroidal Anti-Inflammatory Drugs and Cancer Prevention
Information from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.
Aspirin
Low-Dose Aspirin Fails to Protect Women Against Cancer
(Posted: 07/27/2005) - Low-dose aspirin taken every other day failed to protect women from developing cancer, according to results from a 10-year, randomized trial called the Women's Health Study. However, researchers say that more studies are needed to determine whether moderate or high doses of aspirin may yet prove protective.

Lower Breast Cancer Risk With Aspirin Linked to Hormone-Receptor Status
An article from the May 25, 2004, issue of the NCI Cancer Bulletin.

Aspirin Use Is Not Associated with Pancreatic Cancer Mortality, Study Reports
An article from the April 20, 2004, issue of the NCI Cancer Bulletin.

Novel Aspirin Offers Promise for Colorectal Cancer Prevention
An article from the April 5, 2004, issue of the NCI Cancer Bulletin.

Aspirin Protective Against Prostate Cancer, Study Suggests
An article from the March 30, 2004, issue of the NCI Cancer Bulletin.

NCI-Funded Clinical Trials Show Aspirin Reduces Recurrence of Polyps
(Posted: 03/05/2003) - Taking daily aspirin for as little as three years was shown to reduce the development of colorectal polyps by 19 percent to 35 percent in people at high risk for colorectal cancer in two randomized, controlled clinical trials published in today's New England Journal of Medicine.

Aspirin May Reduce Risk of Colon Polyps
(Posted: 04/09/2002, Reviewed: 10/31/2005) - A daily baby aspirin reduced by 19 percent the risk that precancerous polyps (adenomas) in the colon would recur in patients who'd had a previous adenoma surgically removed, researchers reported April 7, 2002, at the American Association for Cancer Research annual meeting.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov